{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PRIME&page=23", "query": { "intervention": "PRIME", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 593, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PRIME&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PRIME&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T12:46:12.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT04379375", "title": "Nudges to Improve Health Behaviors That Limit COVID-19 Spread", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Behavior", "COVID-19" ], "interventions": [ { "name": "Nudge", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-07-27", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379375" }, { "nct_id": "NCT01922986", "title": "Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "active rTMS", "type": "DEVICE" }, { "name": "sham rTMS", "type": "DEVICE" }, { "name": "conventional stroke therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2013-09", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01922986" }, { "nct_id": "NCT06881888", "title": "Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Octreotide (drug)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 0, "start_date": "2026-08-31", "completion_date": "2026-10-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06881888" }, { "nct_id": "NCT02296541", "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "Placebo for MVA-CMDR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 105, "start_date": "2014-12", "completion_date": "2020-07-06", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296541" }, { "nct_id": "NCT02382003", "title": "Web-based Interpretation Training For Anxiety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anxiety" ], "interventions": [ { "name": "Positive Cognitive Bias Modification - Interpretation", "type": "BEHAVIORAL" }, { "name": "50/50 Cognitive Bias Modification - Interpretation", "type": "BEHAVIORAL" }, { "name": "Anxious Imagery Prime", "type": "BEHAVIORAL" }, { "name": "Neutral Imagery Prime", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 807, "start_date": "2016-04", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02382003" }, { "nct_id": "NCT01422226", "title": "Intra Uterine Device Insertion in Nulliparous Women", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Contraception" ], "interventions": [ { "name": "Misoprostol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 3, "start_date": "2011-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01422226" }, { "nct_id": "NCT03141138", "title": "Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue Virus" ], "interventions": [ { "name": "TDENV-PIV", "type": "BIOLOGICAL" }, { "name": "TDENV-LAV F17", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "ALL", "summary": "18 Years to 42 Years" }, "enrollment_count": 40, "start_date": "2017-11-08", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141138" }, { "nct_id": "NCT02752906", "title": "Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningitis", "Meningococcal Meningitis", "Meningococcal Infections" ], "interventions": [ { "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 810, "start_date": "2016-04-15", "completion_date": "2016-12-19", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752906" }, { "nct_id": "NCT01751906", "title": "ABSORB III Randomized Controlled Trial (RCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease", "Coronary Artery Stenosis", "Coronary Disease", "Coronary Stenosis" ], "interventions": [ { "name": "Absorb BVS", "type": "DEVICE" }, { "name": "XIENCE", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2008, "start_date": "2012-12", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-26T12:46:12.672Z", "location_count": 190, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01751906" } ] }